Riboscience reports Phase 1a/b overall survival data for ENPP1 inhibitor RBS2418

Cumberland Pharmaceuticals to submit New Drug Application for ifetroban

Innovent Biologics' sintilimab new indication application accepted for review by NMPA

Genmab reports 28.2-month median overall survival with petosemtamab combination in Phase 2 trial

Akeso presents Phase III HARMONi-GI1 trial results in biliary tract cancer at ESMO 2026

Sichuan Kelun-Biotech announces Phase III OptiTROP-Lung04 study results at 2026 ESMO

Zhejiang Wenda Pharma reports positive NHWD-870 HCl oral BET inhibitor Phase II trial results at 2026 ESMO Annual Meeting

Lunit and Summit to apply AI-powered SCOPE IO platform for tumour microenvironment analysis in immuno-oncology development

Galderma secures Chinese approval for Relfydess to treat frown lines

Alnylam reports positive Phase 1b results for brezosiran in Huntington's disease

Zai Lab reports promising Phase 1b results for zocilurtatug pelitecan in small cell lung cancer

Labcorp, Charles River and FDA collaborate on advancing preclinical methods for evaluating drug abuse potential

HUYABIO International reports positive Phase 3 trial results for HBI-8000 and nivolumab combination

Harbour BioMed's batoclimab injection receives Chinese regulatory approval to treat generalised myasthenia gravis

NFL Biosciences secures regulatory approval to launch Phase 2 trial of NFL-102